The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases

Abstract

Alzheimer’s and Parkinson’s diseases are the most prevalent neurodegenerative disorders. Their etiologies are idiopathic, and treatments are symptomatic and orientated towards cognitive or motor deficits. Neuropathologically, both are proteinopathies with pathological aggregates (plaques of amyloid-β peptide and neurofibrillary tangles of tau protein in Alzheimer’s disease, and Lewy bodies mostly composed of α-synuclein in Parkinson’s disease). These deposits appear in the nervous system in a predictable and accumulative sequence with six neuropathological stages. Both disorders present a long prodromal period, characterized by preclinical signs including hyposmia. Interestingly, the olfactory system, particularly the anterior olfactory nucleus, is initially and preferentially affected by the pathology. Cerebral atrophy revealed by magnetic resonance imaging must be complemented by histological analyses to ascertain whether neuronal and/or glial loss or neuropil remodeling are responsible for volumetric changes. It has been proposed that these proteinopathies could act in a prion-like manner in which a misfolded protein would be able to force native proteins into pathogenic folding (seeding), which then propagates through neurons and glia (spreading). Existing data have been examined to establish why some neuronal populations are vulnerable while others are resistant to pathology and to what extent glia prevent and/or facilitate proteinopathy spreading. Connectomic approaches reveal a number of hubs in the olfactory system (anterior olfactory nucleus, olfactory entorhinal cortex and cortical amygdala) that are key interconnectors with the main hubs (the entorhinal–hippocampal–cortical and amygdala–dorsal motor vagal nucleus) of network dysfunction in Alzheimer’s and Parkinson’s diseases.

Background

Alzheimer’s [1] and Parkinson’s [2] are the first and second most prevalent neurodegenerative diseases, respectively. The etiology, symptomatology and treatment of these diseases are different. However, they share features that have opened new research strategies. First, hyposmia is an early preclinical symptom [3], and the olfactory system is involved due to pathological aggregates in the initial stages [4] (Figs. 1 and 2). Second, several studies have pointed out that associated proteinopathies could act in a prion-like manner, allowing misfolded proteins to induce further misfolding of native proteins and thus propagate through the nervous system [5]. Third, accumulating evidence points towards glia (microglia and astroglia) as key players in these seeding and spreading mechanisms [6]. The present review aims to update the current knowledge on this topic, including data on patients and postmortem tissue as well as experimental models, and advances the hypothesis that certain structures within the olfactory system constitute “hubs” for connectomic propagation [7] of these proteinopathies.

Fig. 1.

Scheme of the lateral view of the human brain showing the main locations of amyloid-β peptide, tau protein and α-synuclein protein during Alzheimer’s and Parkinson’s diseases (a) as well as of a coronal section of the frontal and temporal lobes showing the approximate location of some neuroanatomical structures analysed (b). Note that different rostro-caudal levels have been collapsed in order to show all structures of interest. For abbreviations, see list

Fig. 2.

Scheme of the inferolateral view of the frontal and temporal human lobes showing the main components of the olfactory system. Note that olfactory structures are actually located in the medial temporal lobe and visualized making the temporal lobe transparent. For abbreviations, see list

Main text

The human olfactory system

Amongst the human neuroanatomical classifications, only a few consider, based on phylogenetic and overall ontogenetic data, that the olfactory system is formed by three subsystems: olfactory proper, vomeronasal and terminal [8]. However, it is true that the latter two can only be observed in embryos and fetuses [9], and that the olfactory system is comparatively reduced and the vomeronasal system is vestigial in hominids [10].

The human olfactory system [11] includes the olfactory epithelium, the olfactory bulb and the olfactory cortex (Fig. 2) [12–14]. Primary projections go from the olfactory epithelium to the olfactory bulbs, secondary projections go from the olfactory bulb to the olfactory cortex, and tertiary projections mainly go from the olfactory cortex to other structures within the olfactory system and beyond to the amygdaloid complex, the hippocampal formation and the ventral striatum [14]. This scheme, however, is more complex when centrifugal [15] and contralateral [16] connections of the system are considered.

The intracranial components of the olfactory system can be macroscopically identified in magnetic resonance images (Figs. 3, 4 and 5) as well as macro- and microscopically in images of brain tissue blocks and mosaic-reconstructed Nissl-stained sections and 3D reconstructions (Figs. 6, 7, 8 and 9).

Fig. 3.

Magnetic resonance images of the human brain illustrating the localisation of the olfactory bulb and olfactory peduncle. a: T2 image in an axial plane; b: T1 image in a parasagittal plane (arrow points to the olfactory bulb and arrowhead points to the olfactory peduncle); c: Coronal FLAIR image in the coronal plane. Calibration bar: 10,000 μm. For abbreviations, see list

Fig. 4.

Magnetic resonance images of the human brain illustrating the localisation of rostral olfactory structures. Images correspond to a coronal FLAIR sequence in the coronal plane. Calibration bar: 10,000 μm for (a, c, e) and 2600 μm for (b, d, f). For abbreviations, see list

Fig. 5.

Magnetic resonance images of the human brain illustrating the localisation of caudal olfactory structures. Images correspond to a coronal FLAIR sequence in the coronal plane. Calibration bar: 10,000 μm for (a, c, e) and 2600 μm for (b, d, f). For abbreviations, see list

Fig. 6.

Nissl-stained axial mosaic-reconstructed sections of the human olfactory bulb (a) including the different layers (b) as well as the olfactory peduncle (c). High-power magnifications from framed areas in a and c are illustrated in b, d and e. Calibration bar: 1000 μm for a, c, 200 μm for b, 100 μm for d, e. For abbreviations, see list

Fig. 7.

Nissl-stained coronal mosaic-reconstructed sections of the human frontal lobe illustrating olfactory structures (a, b, d, f, h). Panels a, b and h include pictures of tissue blocks from where sections were obtained. Dashed line in a points to the approximate location of the olfactory peduncle. High-power magnifications from framed areas in b, d and f are illustrated in c, e and g, respectively. Calibration bar: 5000 μm for a, b, d, f, h, 2500 μm for c, 1250 μm for e, 1000 μm for g. For abbreviations, see list

Fig. 8.

Three-dimensional reconstructions (StereoInvestigator® software from Micro Bright Field Bioscience) starting sections from the human olfactory bulb (a, b) and frontal lobe (c, e) illustrating different portions of the anterior olfactory nucleus. High-power magnifications of areas indicated by dashed lines in c and e are shown in D and f, respectively. For abbreviations, see list

Fig. 9.

Nissl-stained coronal mosaic-reconstructed sections of the human temporal lobe illustrating olfactory structures (a, b, c). Panels a and c include pictures of tissue blocks from where sections were obtained. Calibration bar: 5000 μm for a–c. For abbreviations, see list

The olfactory epithelium

The olfactory epithelium is located at the dorsal and posterior portions of the nasal cavity [17] and can be distinguished from the respiratory epithelium by the presence of cilia (Fig. 2) [18]. In this epithelium, bipolar receptor cells, microvillar cells, sustentacular cells and basal cells can be distinguished [18], and receptor cells suffer a turnover process during adulthood [19]. These bipolar receptor cells display cilia to the nasal cavity and send axons (the fila olfactoria) that cross through the foramina of the cribriform plate of the ethmoid bone to reach the glomeruli of the olfactory bulb [14, 17, 18]. These receptor cells display pathological aggregates in patients with Alzheimer’s and Parkinson’s [20–23].

The olfactory bulb

The olfactory bulb constitutes the first cranial nerve but has some atypical characteristics [24, 25]. The axons from the olfactory receptors do not form a unique bundle; rather, after passing the ethmoid bone, the different fila olfactoria constitute the olfactory nerve. These axons are unmyelinated and covered by ensheathing glia. The bulb has a clear laminar structure (Fig. 6a) that includes the olfactory nerve layer, glomerular layer, external plexiform layer, mitral cell layer, internal plexiform layer, granule cell layer and stratum album (Fig. 6b) [12, 17, 26–28]. Axons from olfactory receptor cells establish synapses in spheres of neuropil in the bulb called glomeruli (asterisks in Fig. 6b). These axons are continuously replaced, and therefore, the circuitry of the olfactory bulb is remodeled. The olfactory nerve constitutes a potential and direct pathway for the entrance of viruses, neurotoxins and other xenobiotics, as well as for therapeutic agents targeting the brain. In the glomeruli, axons from olfactory receptor neurons establish synapses with apical dendrites of mitral and tufted cells. These projection cells are locally modulated by periglomerular and granule cells [29]. From the olfactory bulb (Figs. 3a, arrow in 3b, 6a), mitral and tufted cells send their axons to form a long bundle, the olfactory peduncle (arrowhead in Figs. 3b, 6a, c), coursing between the straight gyrus and the medial orbital gyrus (Figs. 3c, 4a, b, 7a), to join the basal frontal lobe and reach different olfactory structures: anterior olfactory nucleus, piriform cortex, olfactory tubercle, cortical amygdala, medial amygdala, cortex–amygdala transition zone and olfactory portion of the entorhinal cortex [12–14, 30] (Figs. 4, 5, 7, 8, 9).

The anterior olfactory nucleus

The human anterior olfactory nucleus is composed of at least seven divisions along the olfactory system (Fig. 2): bulbar (including several components) (Figs. 6a, d, 8a, b); intrapeduncular (Figs. 6c, e); retrobulbar (Figs. 7b, c, 8c–f); and anterior (Figs. 7d, e, 8c–f) and posterior (Figs. 7f, g, 8c–f) cortical portions with their medial and lateral components [12, 26, 31]. This organization into divisions appears to be exclusive to primates [12, 32] and humans [12, 26, 33], with all divisions being preferentially affected by proteinopathies [4, 31, 34–37].

The olfactory cortex

Along the olfactory system (Fig. 2), when the olfactory peduncle approaches the anterior perforated substance (Figs. 4a, b, 7a), it contacts the basal frontal lobe (Fig. 4c, d, 7b, c) and flattens out as the olfactory trigone, thus constituting the medial and lateral olfactory striae (Figs. 7d, e) [17]. The medial olfactory stria, much reduced, reaches the cortical anterior medial anterior olfactory nucleus and extends towards the diagonal band of Broca. The lateral olfactory stria reaches the cortical anterior lateral anterior olfactory nucleus, extending further laterally (Figs. 4e, f, 7d, e). Caudally, the olfactory tubercle, the cortical posterior medial anterior olfactory nucleus and its lateral divisions, and the frontal piriform cortex are reached (Figs. 7f, g, h). At the level of the limen insulae and beyond, in addition to some of the previous structures, the temporal piriform cortex, the olfactory entorhinal cortex, the periamygdaloid cortex, the cortex–amygdala transition zone and the medial amygdala (Figs. 5a–f, 9a–c) are also included among the olfactory-recipient structures. It should be noted that there is no direct evidence in humans of the exact extension of the olfactory cortex, but it has been studied through functional magnetic resonance imaging, diffusion tensor imaging and tractography and comparative neuroanatomical studies [12, 30, 32, 38–41].

Alzheimer’s and Parkinson’s diseases

Although Alzheimer’s disease is mostly idiopathic (> 95% of patients suffer the sporadic form) [1], there is growing evidence of a genetic predisposition (60–80% attributable risk) [42]. Mutations in apolipoprotein E4 (APOE4) are the main risk factor, with the lifetime risk for Alzheimer’s disease being more than 50% for APOE4 homozygotes and 20–30% for APOE3 and APOE4 heterozygotes [43]. The disease has an estimated prevalence of 10–30% in the population > 65 years of age, with an incidence of 1–3% [1, 44, 45]. Clinical diagnosis is based on cognitive deficits [44], particularly anterograde (episodic) amnesia [46]. Pathophysiologically, it is a consequence of the imbalance in the production and clearance of the amyloid-β (Aβ) peptide from the extracellular space of the brain, which subsequently may induce (or be permissive of) tau aggregation by as yet unknown mechanisms [1, 45, 47, 48].

Neuritic plaques mostly composed of amyloid-β peptide (Fig. 10a, b) and neurofibrillary tangles of tau protein (10C, D) are the neuropathological hallmarks of the disease [45, 47–49]. These aggregates characterize a six-stage predictable sequence beginning in the locus coeruleus, olfactory bulb and (trans)entorhinal cortex and subsequently extending to the rest of the temporal cortex and other isocortical areas (Fig. 1) [45, 47, 49].

Fig. 10.

Immuno-stained sections of the human brain illustrating the labelling against amyloid-β peptide (a), tau protein (c) and α-synuclein protein (e). High-power images shown in b (arrow points to a plaque), d (arrow points to a dystrophic neurite) and f (arrow points to a Lewy body and arrowhead to a Lewy neurite) correspond to frames in a, c and e, respectively. Calibration bars: 250 μm for a, c, e, 20 μm for b, d, f. For abbreviations, see list

In Parkinson’s disease, two centuries after its nosologic description, research criteria for the diagnosis are still subject of debate [50]. Etiologically, most cases are idiopathic, with inherited genetic forms only accounting for a small percentage (5–10%) of diagnosed patients [2], particularly in monogenic forms of Parkinson’s disease. SNCA, which encodes the protein α-synuclein, was the first gene identified as being linked to the disease [51]. Mutations in LRRK and parkin are the most common causes of dominantly and recessively inherited cases, respectively [52]. Worldwide incidence estimates of Parkinson’s disease range from 5 to > 35 new cases per 100,000 individuals annually, with the global prevalence being 0.3% and increasing to > 3% in people over 80 years of age [2]. Clinical diagnosis is based on bradykinesia plus muscular rigidity and/or resting tremor and/or postural instability [52]. Nonmotor symptoms are gaining interest for early diagnosis [2]. Neuropathologically, Parkinson’s disease includes neuronal loss in the ventrolateral tier of the substantia nigra pars compacta and the corresponding striatal dopamine denervation and widespread intracellular α-synuclein accumulation [2, 53, 54].

Lewy bodies and neurites (Fig. 10e, f) [55] contain ubiquitin but are mostly made up of aggregated α-synuclein [56], which is encoded in a gene that has been identified in familial Parkinson’s disease [51]. These aggregates occur initially in cholinergic and monoaminergic brainstem neurons and in neurons in the olfactory system, and they are also found in the limbic and isocortical regions with disease progression (Fig. 1) [57, 58]. In comorbid patients also suffering from Alzheimer’s disease, α-synucleinopathy exhibits a different pattern concentrated mostly in limbic brain regions [59].

Common traits of Alzheimer’s and Parkinson’s diseases

As described above, Alzheimer’s and Parkinson’s diseases have a number of etiology, symptomatology and treatment differences. Both disorders share, however, a long prodromal period during which most patients suffer hyposmia and associated proteinopathies that give rise to aggregates that accumulate initially and preferentially in olfactory structures.

Prodromal period: hyposmia

There is growing evidence that both Alzheimer’s [60–62] and Parkinson’s [63–67] have a long period of progression of years, even decades, before clinical diagnosis can be established. This therapeutic window should be exploited to improve early diagnosis.

Olfactory dysfunction has been proposed as an early marker of both Alzheimer’s [68] and Parkinson’s [69] diseases. This topic has recently gained some attention, but its use in clinical diagnosis is still not routine, due in part to the difficulty in distinguishing hyposmia (threshold and discriminative olfactory deficits) caused by different neurodegenerative diseases and aging [3, 70]. The neural substrates underlying hyposmia are largely unknown. It has been proposed damage in the olfactory epithelium, olfactory bulb and/or olfactory cortex or even involvement of centrifugal neuromodulator systems, such as the cholinergic system [3].

For Alzheimer’s disease, a prospective study including a cohort of 757 participants with a follow-up at 2 years and 4 years, using the University of Pennsylvania Smell Identification Test (UPSIT), suggested that odor identification was superior to verbal episodic memory deficits in predicting cognitive decline [71]. In the same vein, odor identification has been demonstrated to be useful for identifying Alzheimer’s disease pathology in healthy high-risk individuals [72]. A report among individuals with normal cognition, amnestic mild cognitive impairment, nonamnestic mild cognitive impairment and dementia indicates that olfactory impairment predicts amnestic mild cognitive impairment and progression to Alzheimer’s disease [73]. Analysis of odor identification, cognition and markers in cerebrospinal fluid revealed that lower odor identification scores correlated with increased tau concentrations. Odor identification impairment may therefore be used as a marker of neuronal damage rather than amyloid pathology [74]. It has been demonstrated that olfactory dysfunction in the presence of one or more APOE-ϵ4 alleles is associated with a high risk of cognitive decline [75, 76]. These data are supported by experimental models [77]. A recent review of olfactory and other sensory impairments as biomarkers concluded that odor identification, odor familiarity and odor recognition clearly allow discrimination between patients with Alzheimer’s disease, patients with mild cognitive impairment, those at risk of Alzheimer’s disease (amyloid-β deposition or genetic predisposition) and cognitively normal individuals [78]. Interestingly, a comparison between patients with Alzheimer’s disease-related cognitive impairment and Lewy body-related cognitive impairment revealed that cortical atrophy in the former and white matter abnormalities in the latter play key roles in olfactory deficits [79].

For Parkinson’s disease, olfactory dysfunction has been shown to be present in approximately 90% of preclinical cases and can precede the onset of motor symptoms by decades [80]. Prospective studies have also shown that hyposmia is correlated with at least a 10% increased risk of developing Parkinson’s disease [81], that it can predate clinical Parkinson’s disease by at least 4 years [82] and that, among diagnosed patients, severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson’s disease [83]. Recent advances optimizing olfactory testing may help to generalize its use in the clinical evaluation of Parkinson’s disease [84].

Etiology: idiopathic diseases with early aggregates in the olfactory system

The etiologies of both diseases, although largely unknown, are substantially different, and although both are idiopathic, the contributions of different factors are still not fully understood. They share mitochondrial dysfunction, oxidative stress imbalance, perturbation of calcium homeostasis, neurotransmission alteration and protein misfolding that yields aggregates [1, 2].

In Alzheimer’s disease, tau accumulation is probably the best histopathological indicator of clinical progression [85]. Interestingly, early descriptions showed that the cortex of “associative” areas including the frontal, temporal and parietal lobes was severely involved, whereas motor, somatosensory and primary visual areas were virtually unaffected – with the exception of the olfactory system, which was invariably and massively affected [86, 87]. Following this observation, Braak’s proposed staging included neurofibrillary tangles and neuropil threads in the transentorhinal cortex (stages I–II), limbic structures (stages III–IV) and isocortex (stages V–VI) [88], with primary cortices being largely preserved [89]. The primary visual cortex, for instance, is not involved until stage VI, which is a diagnostic criterion. Improvement in this staging system using paraffin sections and hyperphosphorylated tau protein antibody allowed observation of the development of the earliest lesions in subcortical brain regions in the locus coeruleus [49]. Given their invariable and early involvement, the locus coeruleus and other structures within the olfactory system have been considered “hubs” for proteinopathy spreading (Fig. 1) [90].

Early reports on the olfactory bulbs in Alzheimer’s disease indicated the presence of neurofibrillary tangles, limited to the anterior olfactory nucleus, accompanied by cell loss [91]. Neuritic plaques were also found in the anterior olfactory nucleus, as well as neurofibrillary tangles and neuropil threads in the anterior olfactory nucleus and in other layers of the olfactory bulb [36]. Since then, a number of studies have confirmed these findings, suggesting that this pathology starts very early and correlates with Braak staging [92–98]. Amyloid-β and tau were also reported in the cortical anterior olfactory nucleus [34] and the piriform cortex [99]. Finally, tau and amyloid-β aggregates have also been described in dystrophic neurites of the olfactory epithelium of patients with Alzheimer’s disease, which is symptomatic of brain pathology [20–22]. As a result, the olfactory system has gained renewed interest in research into proteinopathies associated with Alzheimer’s disease [4, 100].

In Parkinson’s disease, very early immunoreactive Lewy bodies and neurites have been described in the dorsal glossopharyngeus–vagus complex and in the olfactory bulb, olfactory tract and anterior olfactory nucleus [101]. This initial description was followed by a complete staging proposal: 1) medulla oblongata (dorsal IX/X motor nucleus) and anterior olfactory nucleus; 2) medulla oblongata and pontine tegmentum (raphe nuclei and coeruleus–subcoeruleus complex); 3) midbrain (substantia nigra, pars compacta); 4) basal prosencephalon and mesocortex (transentorhinal region) and allocortex (CA2); 5) high-order association areas of the isocortex; and 6) first-order sensory association areas and premotor isocortex (Fig. 1) [57]. Less than 10% of cases examined (which, interestingly, had concomitant Alzheimer’s disease) showed a different pattern: olfactory structures and the amygdala were predominantly involved with a virtual absence of brainstem pathology [59, 102].

The pathology has historically been found to preferentially affect the olfactory system. Early reports described, using ubiquitin antibodies, Lewy bodies in the olfactory bulb and tract, particularly in the anterior olfactory nucleus [103]. Misrouted olfactory fibers in the external plexiform layer of the olfactory bulb formed glomerulus-like structures in Parkinson’s disease cases [104]. Immunohistochemistry against α-synuclein in patients with dementia, including those suffering from Parkinson’s disease, revealed Lewy-type pathology along the olfactory system, including not only the olfactory bulb and olfactory tract but also the anterior olfactory nucleus (cortical) and olfactory cortex [105]. The pathology has been suggested to be particularly abundant in the seven described divisions of the anterior olfactory nucleus [31, 35]. Among the primary olfactory cortex, the pathology was significantly more severe in the temporal division of the piriform cortex than in the frontal division of the piriform cortex, olfactory tubercle or anterior portions of the entorhinal cortex [106]. Reports on the olfactory bulb of aged people with different neuropathological diagnoses have revealed a high incidence of Lewy-body-related α-synucleinopathy that presumably extends from the periphery to the anterior olfactory nucleus [37]. In fact, olfactory bulb α-synucleinopathy is considered highly specific and highly sensitive for Lewy body disorders, to the point that it has been suggested that olfactory bulb biopsies be performed to confirm the diagnosis in subjects prior to surgical therapy [107]; however, there is controversy over this suggestion given the invasiveness of the procedure [108, 109]. Lewy body pathology has also been detected in the olfactory epithelium of patients with Parkinson’s disease [23], as has been the case for prion protein in Creutzfeldt-Jakob disease [110]. Therefore, the olfactory system is being regarded as of particular interest in the study of α-synucleinopathy in Parkinson’s disease [4, 30, 111].

Morphometry: magnetic resonance imaging and stereological analysis

In Alzheimer’s disease, hippocampal and parahippocampal atrophy measured using magnetic resonance imaging have been widely reported as having a high correlation with cognitive and sensory tests [112]. The medial temporal lobe cortex, in particular the entorhinal cortex, is quite reduced, and this is correlated with episodic memory impairment [113–115]. Olfactory cortex degeneration has been associated with a decline in olfactory activity in Alzheimer’s disease and subjects with mild cognitive impairment [116]. Similarly, olfactory bulb atrophy has also been reported [117] and has been linked to atrophy of the medial temporal lobe [118]; however, this atrophy does not appear to be associated with olfactory dysfunction [119].

These findings have been paralleled by studies in postmortem tissue using stereological methods [120]. The CA1 hippocampal field (68%) [121] and layers IV and II of the entorhinal cortex (40–70% and 60–90%, respectively, depending on the severity of cases) [122] have been reported as the most distinctive regions regarding neuron loss. In fact, neuronal loss is detectable in mild Alzheimer’s disease but not in preclinical cases or those associated with normal aging [123, 124]. Volume and neuron numbers significantly decline with disease duration, which suggests that hippocampal atrophy is a result of neuronal loss [125]. For the oldest cases, the Clinical Dementia Rating appears to be more dependent on damage to other hippocampal subdivisions than on severe neurofibrillary tangle formation in the entorhinal cortex and CA1 field [126]. Other studies exploring the relationship between the Clinical Dementia Rating and hippocampal neuronal pathology have indicated a dissociation between the progression of neurofibrillary tangles and neuronal loss in the entorhinal cortex and CA1 field, and only a limited amount of cognitive dysfunction has been attributed to Alzheimer’s neuronal pathology in these areas [127, 128]. In the olfactory bulb, no changes in the total number of cells or the total number of mitral cells were reported, but rather a significant decrease in the volume of the olfactory bulb and in the total number of cells in the anterior olfactory nucleus [93]. Other studies have confirmed a significant volume decrease and an increase in periglomerular dopaminergic cells in Alzheimer’s patients compared to controls [129].

In Parkinson disease, voxel-based morphometry studies have demonstrated that olfactory dysfunction in Parkinson’s disease is related to olfactory-specific regions, namely, in the right amygdala and piriform cortex [130]. Olfactory dysfunction has been correlated not only with piriform but also with orbitofrontal cortex atrophy [131]. Other studies have explored the controversial association between olfactory performance and gray matter reduction in olfactory areas [132, 133]. A reduced disgust response has also been linked to atrophy of the piriform and orbitofrontal cortex [134].

At the same time, morphometric studies in postmortem human tissue have revealed cell loss of dopaminergic neurons in the ventral tier of the substantia nigra pars compacta due to aging [135, 136] and dementia with Lewy bodies [137], and this is particularly marked in Parkinson’s disease [138, 139]. This cell loss appears to be progressive during the prodromal period, but the correlation with Lewy body pathology is unclear [140, 141]. Global counting of neocortical neurons does not reveal significant cell loss in Parkinson’s disease compared with controls [142]. In limbic structures, however, the situation is contradictory. In the amygdala, the volume was reduced by 20%, and cell loss (in parallel with increased Lewy pathology) was significant in the cortical and basolateral nuclei; clinically, this was correlated with anosmia and visual hallucinations, respectively [143]. In contrast, in the different hippocampal fields [144], no differences have been found in the numbers of neurons or glial cells [145]. Interestingly, in olfactory structures, the data are more uniform. Profound cell loss has been reported in the olfactory bulb and tract, particularly in the anterior olfactory nucleus, showing a strong correlation with disease duration and paralleling Lewy pathology [146]. Data on cell losses in the olfactory bulb and its correlation with Lewy pathology have been corroborated [140]. No significant volume changes have been reported, but an increase in dopaminergic cells has been cited as a compensatory mechanism [129, 147], which is significantly higher in males [148].

Proteinopathies

Transcriptomic [149] and proteomic [150] data within the Human Brain Proteome Project are very useful for understanding proteinopathies in the olfactory system. This kind of analysis has been particularly useful in neurodegenerative diseases [151], including Alzheimer’s and Parkinson’s diseases [152]. In the olfactory bulb of the APP/PS1 model of Alzheimer’s disease, early cytoskeletal disruption and synaptic impairment have been reported, whereas studies in the Tg2576 model have allowed us to further characterize the dysregulation of molecular homeostasis [153, 154]. Analysis of human samples has allowed us to characterize proteomic changes along staging in Alzheimer’s [155–157] and Parkinson’s [158, 159] diseases.

Neuritic plaques mainly, but not solely, consist of amyloid-β aggregates. Amyloid-β is derived through the proteolytic cleavage of amyloid precursor protein (APP) by a heterogeneous family of enzymes (γ-secretases and β-secretases, including presenilin 1 and 2), giving rise to peptides ranging from 38 to 43 amino acids. Several lines of evidence have suggested that amyloid-β accumulation and conformational changes from an α-helix to a β-sheet structure may be crucial in the pathogenesis of the disease [1].

Tau is a protein highly present in neurons and originally described by its ability to bind and stabilize microtubules. Beyond that, tau mediates axonal transport, synaptic function and signaling pathways. Knowledge of its physiological roles and posttranslational modifications is necessary to understand its implications in the pathogenesis of Alzheimer’s disease [160].

The normal function of α-synuclein 140-amino-acid protein is not well understood, but it is present in the cytosol, likely the mitochondria and the nucleus, and it probably participates in synaptic-vesicle fusion, trafficking inside the cell and mitochondrial function. During the pathogenic process, α-synuclein misfolds to form β-rich sheets, acquires toxic traits and becomes insoluble when monomers form oligomers, protofibrils and eventually fibrils that yield Lewy pathology [2, 161].

Prion-like spreading

Over time, the prion-like hypothesis in neurodegenerative diseases has gained interest, as it is supported by data obtained in postmortem tissue, patients and experimental models in vitro and in vivo. In Alzheimer’s disease, there is growing evidence for both amyloid-β and tau acting in a prion-like manner [162], as well as for α-synuclein in Parkinson’s disease [163–171]. In Parkinson’s disease in particular, the debate [172] for [173] and against – considering that this disease cannot be explained simply from a prionoid perspective – [174] is ongoing.

There was a paradigmatic change in the approach to neurodegenerative diseases after the proposal of neuropathological staging in Alzheimer’s [49, 88] and Parkinson’s [57, 175] diseases. This proposal was, in most cases, reproducible, accumulative and predictable, and it followed a sequence of neuronal connected regions that perfectly matched the idea of prion-like proteinopathy spreading [176]. For Alzheimer’s disease, the idea of a possible transmission of tau from the locus coeruleus to the transentorhinal cortex via neuron-to-neuron transmission and transsynaptic transport has been proposed after the observation of pretangles within noradrenergic coeruleus projection neurons in the absence of any pathology in the medial temporal lobe [176, 177]. For Parkinson’s disease, the proposed route of transmission would begin in the gastrointestinal mucosa and, via postganglionic enteric neurons, would enter the central nervous system retrogradely through poorly myelinated vagal neurons [176, 178, 179]. Alternatively, a nasal route through the olfactory epithelium and bulb – the olfactory vector hypothesis [180] – was also proposed, constituting the dual-hit hypothesis according to which spread may occur anterogradely through the olfactory epithelium and/or retrogradely through the intestinal mucosa [181, 182]. This latter possibility has been reinforced by the fact that truncal vagotomy appears to be protective against this disorder [183], although human autopsy evidence does not support this possibility and the debate remains open [184].

In vitro and in vivo data have shown that wild-type human tau protein, but not mutated tau, injected in the hippocampus of rats is able to propagate to olfactory structures through transsynaptic mechanisms [185]. In vitro experiments with α-synuclein support the notion that protein aggregation is not the primary cause of cytotoxicity [186]. Lewy body extracts from patients have demonstrated their toxicity and spreading capacity among neurons and astrocytes [187]. Injections in the olfactory bulb [188] or anterior olfactory nucleus [16] induced distant or contralateral α-synucleinopathy, respectively.

Connectome and pathology

Neurodegenerative diseases can only be approached from a global perspective that encompasses the micro- to the macroscale. Neuronal activity is affected at many levels, including genetic, molecular, synaptic, cellular (neurons and glia), local circuits and networks [189]. In the previous sections, microscale levels have been considered. In this section, cellular and connectomic levels will be discussed, focusing on the selective involvement (vulnerability or resistance) of certain neuronal (Figs. 11a–c) and glial (Figs. 11d–i) populations and how nodes and hubs within the olfactory system through their connections can help explain the pathophysiology of neurodegenerative diseases (Fig. 1).

Fig. 11.

Immuno-stained sections of the human brain from non-pathological (a, d, g), Parkinson’s disease (B, E, H) and Alzheimer’s disease (c, f, i) cases illustrating the labelling against markers of neurons (Neu-N) (a, b, c), microglia (Iba-1) (d, e, f) and astroglia (GFAP) (g, h, i). Dashed lines indicate the boundaries of different portions of the anterior olfactory nucleus. Calibration bar: 125 μm for a–i. For abbreviations, see list

In Alzheimer’s and Parkinson’s diseases, the specific cell types that are prone to developing proteinaceous inclusions are projection cells with long, unmyelinated or sparsely myelinated axons. Among the olfactory cortical areas, in Alzheimer’s stages I–II and in Parkinson’s stage 4, the pathological process reaches the entorhinal cortex and hippocampus, progressing thereafter to the isocortex. Regarding neuronal vulnerability, data in the literature are not homogeneous in the olfactory system [100]. Some data conclude the resistance of interneuron populations expressing calcium-binding proteins in Alzheimer’s disease in the pirirform cortex [99], whereas others suggest a selective vulnerability depending on entorhinal subfields [190]. Several investigations have pointed out the high vulnerability of d somatostatinergic neurons in the olfactory system in Alzheimer’s disease [34, 99, 191] (Figs. 12 A–D). Glial cells have always been regarded as subordinates of neuronal function, either with immune and phagocytic capacity (microglia) (Figs. 11d–f) or the responsible of homeostasis and metabolic neuronal maintenance, including establishment of the blood–brain barrier (astroglia) (Figs. 11g–i). The role of glial cells on connectomic interactions is just beginning to be envisaged.

Fig. 12.

Immuno-fluorescent sections of the human olfactory bulb from an Alzheimer’s disease case illustrating the labelling against markers of tau protein (a), amyloid-β (b) and somatostatin (c) as well as the merged image (d). Calibration bar: 500 μm for a–d, 60 μm for e-h. For abbreviations, see list

The term connectome, first used more than one decade ago [192], aims to describe the structural and functional connectivity of the human brain among connected (nodes) and highly connected (hubs) regions from an -omic perspective and to explore similarities and differences across disorders, including disconnectivity [7]. The connectomic approach has allowed mapping lesion symptoms into brain networks [193] as well as identifying hubs, such as the amygdala [194] and the medial temporal lobe [195], namely, the hippocampus [196], which are generally implicated in the anatomy of brain disorders such as depression and Alzheimer’s disease, respectively.

Imaging techniques for visualizing the pathophysiology of Alzheimer’s disease in patients have revealed that the earliest deposits of amyloid-β appear in the medial parietal cortex in the first stages of the disease, whereas aggregates of tau occur earlier in the medial temporal lobe in cognitively healthy older people. It is debated whether the first deposits of tau in the medial temporal lobe represent the early stages of the disease or are somewhat innocuous until the presence of amyloid-β [197]. Similarly, it has been proposed that amyloid-β oligomers initially produced in isocortical neurons, including the synaptic terminal on entorhinal cortex neurons, may subsequently catalyze the formation of tau oligomers that could spread to the hippocampal formation, locus coeruleus, basal forebrain cholinergic neurons, raphe nuclei, and back to the isocortex [198]. Alternatively, it has been proposed that one potential trigger for tau protein hyperphosphorylation and conformation change may be a nonendogenous pathogen that develops tau lesions, beginning “in phylogenetically late-appearing and ontogenetically late-maturing neurons that are connected via their axons” [90] (Fig. 1).

Neuropathological analyses have illustrated that tau aggregates form early and preferentially occur in the locus coeruleus, olfactory bulb/anterior olfactory nucleus, amygdala [199] and entorhinal/transentorhinal cortex – three potential hubs. The latter constitutes a bottleneck for information entrance to and retrieval from the cortex through the hippocampus that likely helps to explain its relevance in the disease [90]. On the other hand, the olfactory bulb and, particularly, the different divisions of the anterior olfactory nucleus, are also early locations that are preferentially affected by Alzheimer’s pathology, likely due to their reciprocal and contralateral connections with olfactory structures as well as more distant regions such as the temporal cortex [16, 32, 100]. It is important to note that there is a part of the entorhinal cortex that receives direct olfactory information [30, 38], thus constituting a direct connection among hubs in the olfactory system and those in the entorhinal–hippocampal–cortical loop, thus allowing reciprocal interactions between the earliest involved regions in Alzheimer’s disease (Fig. 1).

In Parkinson’s disease, postmortem investigations have allowed a detailed reconstruction of the potential neuronal connections involved, including the central [55, 57] and peripheral nervous systems [200], in progressive stages: 1) enteric nervous system, olfactory bulb and motor nucleus of the vagus/glossopharyngeal nerves; 2) raphe nuclei and locus coeruleus; 3) substantia nigra and amygdala; 4) hippocampus and temporal mesocortex; 5) high-order association cortex; and 6) primary sensory cortex. Accordingly, structures in the first stages constitute potential hubs for α-synuclein spreading [30]. In the amygdaloid complex, for instance, the central nucleus appears to be crucial for synucleinopathy propagation in the forebrain [55, 199, 201]. Given their position and connectivity, the olfactory bulb [202] and particularly the anterior olfactory nucleus [30] are crucial for centripetal spreading of Lewy pathology (Fig. 1).

In fact, potential digestive mucosa pathology can retrogradely spread to the dorsal motor nucleus of the vagus nerve. Within the amygdala, the central nucleus is the output component of the amygdaloid complex, intervening in sympathetic and parasympathetic responses mediated by the amygdala. Therefore, the central amygdaloid nucleus is connected to the dorsal motor nucleus of the vagus. Interestingly, the central nucleus shows denser Lewy pathology among the amygdaloid nuclei [143, 201]. On the other hand, the amygdala (cortical) receives direct olfactory inputs, and the different amygdaloid nuclei are highly interconnected, including the periamygdaloid cortex and the central nucleus. Thus, another important interconnection occurs between hubs in the amygdala–parasympathetic system and those of the olfactory system. This second network, of course, is also primarily connected to the entorhinal–hippocampal–cortical cluster [30], which may help explain cases of Lewy pathology concentrated in the forebrain when Alzheimer copathology occurs (Fig. 1) [59, 102].

Conclusions

Alzheimer’s and Parkinson’s diseases are prevalent neurodegenerative disorders with a long prodromal period during which preclinical manifestations such as hyposmia occur. Associated proteinopathies are amyloid-β and tau and α-synuclein. Aggregates occur in the olfactory system, particularly in the anterior olfactory nucleus, early and in a preferential manner. The olfactory system is composed of a number of mostly cortical structures along the frontal and temporal lobes. Magnetic resonance imaging data and volumetric analyses have revealed some volume changes that must be complemented by histological reports to assess whether morphometric changes are due to neuronal and/or glial loss or parenchymal remodeling. Prion-like hypotheses applied to proteinopathies associated with Alzheimer’s and Parkinson’s diseases have suggested that misfolded proteins can “seed” and induce misfolding of native proteins, “spreading” through neurons and glia. Accumulated data from patients, postmortem tissue and in vivo and in vitro experiments support this hypothesis, whereas arguments against it highlight that direct proof is still missing. The connectomic perspective explores the factors providing resistance or vulnerability to neuronal populations and the positive and/or negative role of protein spreading. Hubs in the olfactory system (e.g., the anterior olfactory nucleus, amygdala and entorhinal cortex) are highly interconnected with hubs in the entorhinal–hippocampal–cortical and amygdala–parasympathetic clusters, which are essential for protein spreading in Alzheimer’s and Parkinson’s diseases, respectively. These hubs within the olfactory system should be particularly considered in future diagnostic, prognostic and therapeutic approaches using molecular imaging with PET.

Abbreviations

AC

Amygdaloid complex

Acc

Nucleus accumbens

AG

Ambiens gyrus

AON

Anterior olfactory nucleus

AONb

Anterior olfactory nucleus, bulbar

AONc

Anterior olfactory nucleus, cortical

AONca

Anterior olfactory nucleus, cortical anterior

AONcal

Anterior olfactory nucleus, cortical anterior lateral

AONcam

Anterior olfactory nucleus, cortical anterior medial

AONcp

Anterior olfactory nucleus, cortical posterior

AONcpl

Anterior olfactory nucleus, cortical posterior lateral

AONcpm

Anterior olfactory nucleus, cortical posterior medial

AONi

Anterior olfactory nucleus, intrapeduncular

AONrb

Anterior olfactory nucleus, retrobulbar

CA1-CA3

Hippocampal fields

cc

Corpus callosum

CxA

Cortex–amygdala transition zone

db

Diagonal band (of Broca)

EC

Entorhinal cortex

ECo

Entorhinal cortex, olfactory

EPL

External plexiform layer

FL

Frontal lobe

FLAIR

Fluid Attenuated Inversion Recovery.

FLV

Frontal horn of lateral ventricle

GCL

Granule cell layer

GD

Dentate gyrus

GL

Glomerular layer

H

Hippocampus

IG

Insular gyrus

IPL

Internal plexiform layer

LC

Locus coeruleus

Li

Limen insulae

lolf

Lateral olfactory radiation

MCL

Mitral cell layer

Me

Medial amygdala

molf

Medial olfactory radiation

MOrG

Medial orbital gyrus

OB

Olfactory bulb

OE

Olfactory epithelium

ONL

Outer nerve layer

OP

Olfactory peduncle

opt

Optic tract

ot

Olfactory tract

OT

Olfactory tubercle

ox

Optic chiasm

PAC

Periamygdaloid cortex

PET

Positron emission tomography.

PHG

Parahippocampal gyrus

Pir

Piriform cortex

PirF

Piriform cortex, frontal

PirT

Piriform cortex, temporal

PMOL

Posteromedial orbital lobule

PRC

Perirhinal cortex

R

Raphe nuclei

S

Subicular complex

SA

Stratum album

SG

Straight gyrus

SN

Substantia nigra

TLV

Temporal horn of the lateral ventricle

TP

Temporal pole

Un

Uncus

X

Nucleus of the vagus nerve

Authors’ contributions

IUB and DSS wrote the first draft of the manuscript. AFC, ERC, MGR, SVC, VAL and AMM contributed to sections 3, 6 and 7 including figures. JPCR, MJGA and JVG contributed to sections 1, 2 and 4 including figures. FRC, LGL and AR contributed to sections 1, 2 and 5 including figures. AMM+ coordinated the work. All authors read and approved the final manuscript.

Funding

Funding agencies: Sponsored by the Spanish Ministry of Economy and Competitiveness/ERDF (grant no. SAF2016–75768-R) and the Autonomous Government of Castilla-La Mancha/ERDF (grant no. SBPLY/17/180501/000430) to AMM.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Not applicable.